Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2026-02-21 @ 3:14 PM
Study NCT ID:
NCT00658320
Status:
COMPLETED
Last Update Posted:
2013-06-21
First Post:
2008-04-10
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids
Sponsor:
Novartis
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Kidney Transplantation | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Renal transplantation | View |
| None | everolimus | View |
| None | mycophenolate mofetil | View |
| None | cyclosporine | View |
| None | corticosteroid | View |
| None | basiliximab | View |
| None | Banff diagnosis | View |
| None | Acute rejection | View |
| None | Therapeutic drug monitoring (TDM) | View |
| None | de novo renal transplant recipient | View |